Funder: Alzheimer's Association
Due Dates: March 26, 2026 (LOI) | April 30, 2026 (Full application)
Funding Amounts: Phase 1: up to $1,000,000 total; Phase 2-3: up to $2,000,000 (rarely up to $3,000,000); max 2–3 years.
Summary: Supports translational research advancing combination clinical trials for Alzheimer’s disease, prioritizing biomarker-informed studies that integrate at least two therapeutic strategies.
Key Information: LOI required; late submissions not accepted; only one application per applicant per cycle.